Suppr超能文献

与医疗保险处方药药物治疗管理计划相关的种族和民族差异。

Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.

机构信息

Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.

Gillings School of Global Public Health, University of North Carolina at Chapel Hill.

出版信息

J Manag Care Spec Pharm. 2024 Jun;30(6):609-616. doi: 10.18553/jmcp.2024.30.6.609.

Abstract

Medicare's Part D Medication Therapy Management (MTM) programs serve approximately 4.5 million eligible beneficiaries. Prior research suggested that the thresholds to enter Part D MTM programs would disproportionately favor White beneficiaries compared with Black or Hispanic beneficiaries. This article summarizes those initial studies and compares the results with more recent analyses of racial and ethnic differences in MTM program enrollment, which, in general, show higher odds of MTM enrollment for minority beneficiaries compared with White beneficiaries. Disparities in the utilization of comprehensive medication review (CMR), a core MTM service, are also discussed. Although trends vary, disparities exist for various minority groups. For example, Black beneficiaries and Hispanic beneficiaries are less likely to be offered a CMR compared with White beneficiaries. Additionally, minority (Asian, Hispanic, and North American Native) beneficiaries are less likely to receive a CMR after being offered the service compared with White beneficiaries. Black, Hispanic, and Asian beneficiaries are more likely than White beneficiaries to have a longer duration between MTM enrollment and CMR offer. There is also a distinct difference in the type of pharmacist (ie, plan pharmacist, MTM vendor pharmacist, or community pharmacist) completing the CMR for certain racial and ethnic groups. For example, compared with White beneficiaries, Black beneficiaries were less likely to receive a CMR from a community pharmacist, whereas Asian beneficiaries were more likely.

摘要

医疗保险的部分 D 药物治疗管理 (MTM) 计划为大约 450 万符合条件的受益人提供服务。先前的研究表明,参与部分 D MTM 计划的门槛将不成比例地偏向于白人受益人,而不是黑人或西班牙裔受益人。本文总结了这些初步研究,并将结果与最近对 MTM 计划参与的种族和族裔差异的分析进行了比较,这些分析普遍表明,与白人受益人相比,少数民族受益人的 MTM 参与率更高。还讨论了综合药物审查 (CMR) 利用方面的差异,CMR 是 MTM 的一项核心服务。尽管趋势有所不同,但各种少数群体之间仍存在差异。例如,与白人受益人相比,黑人受益人和西班牙裔受益人接受 CMR 的可能性较小。此外,与白人受益人相比,少数族裔(亚洲人、西班牙裔和北美原住民)在获得该服务后接受 CMR 的可能性较小。与白人受益人相比,黑人、西班牙裔和亚洲受益人从 MTM 注册到 CMR 提供之间的时间间隔更长。在为某些种族和族裔群体完成 CMR 的药剂师类型(即计划药剂师、MTM 供应商药剂师或社区药剂师)方面也存在明显差异。例如,与白人受益人相比,黑人受益人从社区药剂师那里获得 CMR 的可能性较小,而亚洲受益人则更有可能。

相似文献

1
Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.
J Manag Care Spec Pharm. 2024 Jun;30(6):609-616. doi: 10.18553/jmcp.2024.30.6.609.
3
Racial and ethnic disparities in Medicare Part D medication therapy management services utilization.
Explor Res Clin Soc Pharm. 2023 Jan 11;9:100222. doi: 10.1016/j.rcsop.2023.100222. eCollection 2023 Mar.
4
Comprehensive Medication Review Completion Rates and Disparities After Medicare Star Rating Measure.
JAMA Health Forum. 2024 May 3;5(5):e240807. doi: 10.1001/jamahealthforum.2024.0807.
5
Understanding the Socioeconomic and Geographical Characteristics of Beneficiaries Receiving a Comprehensive Medication Review.
J Manag Care Spec Pharm. 2020 Oct;26(10):1276-1281. doi: 10.18553/jmcp.2020.26.10.1276.
7
8
Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population.
J Am Pharm Assoc (2003). 2012 Sep-Oct;52(5):e87-96. doi: 10.1331/JAPhA.2012.11146.
10
Cost-effectiveness of medication therapy management among Medicare population and across racial/ethnic groups.
Medicine (Baltimore). 2024 May 3;103(18):e37935. doi: 10.1097/MD.0000000000037935.

引用本文的文献

1
Advancing the conversation: 30 years of scholarship in managed care pharmacy.
J Manag Care Spec Pharm. 2025 Jul;31(7):617-626. doi: 10.18553/jmcp.2025.31.7.617.
2
The influence of medication adherence on Medicare Star Ratings: A decade-long analysis of health plan performance.
J Manag Care Spec Pharm. 2025 May;31(5):512-519. doi: 10.18553/jmcp.2025.31.5.512.

本文引用的文献

1
Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.
JAMA Netw Open. 2023 Dec 1;6(12):e2345906. doi: 10.1001/jamanetworkopen.2023.45906.
2
Racial and ethnic disparities in the enrolment of medicare medication therapy management programs.
J Pharm Health Serv Res. 2023 Mar 30;14(2):188-197. doi: 10.1093/jphsr/rmad010. eCollection 2023 Jun.
3
It is time for a new comprehensive medication review quality measure.
J Manag Care Spec Pharm. 2023 Jun;29(6):680-684. doi: 10.18553/jmcp.2023.29.6.680.
4
Racial and ethnic disparities in Medicare Part D medication therapy management services utilization.
Explor Res Clin Soc Pharm. 2023 Jan 11;9:100222. doi: 10.1016/j.rcsop.2023.100222. eCollection 2023 Mar.
5
Social determinants predict whether Medicare beneficiaries are offered a Comprehensive Medication Review.
Res Social Adm Pharm. 2023 Jan;19(1):184-188. doi: 10.1016/j.sapharm.2022.09.015. Epub 2022 Sep 30.
8
Growth In Medicare Advantage Greatest Among Black And Hispanic Enrollees.
Health Aff (Millwood). 2021 Jun;40(6):945-950. doi: 10.1377/hlthaff.2021.00118.
9
Reprint of: Examining Medicare Part D Medication Therapy Management program in the context of mental health.
J Am Pharm Assoc (2003). 2020 Sep-Oct;60(5S):S54-S63. doi: 10.1016/j.japh.2020.08.035.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验